<DOC>
	<DOC>NCT00855465</DOC>
	<brief_summary>The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.</brief_title>
	<detailed_description>Adverse event data will be covered in Adverse events section.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery. All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice Clinical Classification of Pulmonary Hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension</keyword>
	<keyword>PH</keyword>
	<keyword>soluble Guanylate Cyclase Stimulator</keyword>
	<keyword>sGC</keyword>
</DOC>